PPP1R13L
Basic information
Region (hg38): 19:45379638-45406349
Links
Phenotypes
GenCC
Source:
- arrhythmogenic cardiomyopathy with variable ectodermal abnormalities (Definitive), mode of inheritance: AR
- dilated cardiomyopathy (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Cardiomyopathy, arrhythmogenic, with or without ectodermal abnormalities | AR | Cardiovascular | The condition involves severe, early-onset dilated cardiomyopathy, and awareness may enable medical management; Cardiac transplant has been described | Cardiovascular; Craniofacial; Dental; Dermatologic | 28069640; 32666529; 35924320; 35933355 |
ClinVar
This is a list of variants' phenotypes submitted to
- Inborn_genetic_diseases (118 variants)
- not_specified (30 variants)
- not_provided (15 variants)
- Cardiovascular_phenotype (12 variants)
- Arrhythmogenic_cardiomyopathy_with_variable_ectodermal_abnormalities (9 variants)
- Primary_dilated_cardiomyopathy (7 variants)
- PPP1R13L-related_disorder (2 variants)
- Orofacial_cleft (1 variants)
- Cardio-cutaneous_syndrome (1 variants)
- OMIM:607463 (1 variants)
- PPP1R13L-associated_cardiac_phenotype (1 variants)
- Multiple_congenital_anomalies/dysmorphic_syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PPP1R13L gene is commonly pathogenic or not. These statistics are base on transcript: NM_000006663.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 21 | 24 | ||||
| missense | 122 | 130 | ||||
| nonsense | 4 | |||||
| start loss | 0 | |||||
| frameshift | 8 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 6 | 5 | 124 | 28 | 3 |
Highest pathogenic variant AF is 0.000007531784
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| PPP1R13L | protein_coding | protein_coding | ENST00000418234 | 12 | 26716 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.0321 | 0.968 | 125724 | 0 | 16 | 125740 | 0.0000636 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.54 | 392 | 487 | 0.804 | 0.0000324 | 5179 |
| Missense in Polyphen | 94 | 105.77 | 0.88869 | 1093 | ||
| Synonymous | 0.993 | 214 | 233 | 0.917 | 0.0000181 | 1790 |
| Loss of Function | 3.78 | 9 | 32.1 | 0.280 | 0.00000156 | 338 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000207 | 0.000206 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.0000545 | 0.0000544 |
| Finnish | 0.0000462 | 0.0000462 |
| European (Non-Finnish) | 0.0000455 | 0.0000440 |
| Middle Eastern | 0.0000545 | 0.0000544 |
| South Asian | 0.000133 | 0.000131 |
| Other | 0.000167 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Regulator that plays a central role in regulation of apoptosis and transcription via its interaction with NF-kappa-B and p53/TP53 proteins. Blocks transcription of HIV-1 virus by inhibiting the action of both NF-kappa-B and SP1. Also inhibits p53/TP53 function, possibly by preventing the association between p53/TP53 and ASPP1 or ASPP2, and therefore suppressing the subsequent activation of apoptosis. {ECO:0000269|PubMed:10336463, ECO:0000269|PubMed:12134007, ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:15489900}.;
- Pathway
- Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription;Regulation of TP53 Activity through Association with Co-factors;Regulation of TP53 Activity;Transcriptional Regulation by TP53;TNFalpha;p53 pathway
(Consensus)
Haploinsufficiency Scores
- pHI
- 0.225
- hipred
- Y
- hipred_score
- 0.767
- ghis
- 0.579
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.986
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ppp1r13l
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;cardiac right ventricle morphogenesis;ventricular cardiac muscle tissue development;transcription, DNA-templated;apoptotic process;post-embryonic development;embryonic camera-type eye development;multicellular organism growth;hair cycle;positive regulation of cell differentiation;multicellular organismal homeostasis;cardiac muscle contraction;regulation of signal transduction by p53 class mediator
- Cellular component
- nucleus;nucleoplasm;cytosol;cell junction;intercellular bridge
- Molecular function
- transcription corepressor activity;protein binding;transcription factor binding;identical protein binding;cadherin binding